Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Michael Leukam, Matthew Weinstock, Jon E. Arnason, Ranjana H. Advani

Blood (2024) 144 (Supplement 1): 6284.

https://doi.org/10.1182/blood-2024-206520

Published: 2024

Journal Articles

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Genevieve M Gerhard, Robert A. Redd, Poorva Bindal, Carolyn D Alonso, Rushad Patell, Michael Leukam, Jon E. Arnason, Matthew Weinstock, Gottfried von Keudell

Blood (2024) 144 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2024-199156

Published: 2024

Journal Articles

Late Infectious Complications of Chimeric Antigen Receptor T-Cell Therapy Beyond One Year

Sirui Ma, Poorva Bindal, Caitlin Trottier, Pavania Elavalakanar, Laura Dodge, Emma K Logan, Jessica Liegel, Jon E. Arnason, Carolyn D Alonso

Blood (2024) 144 (Supplement 1): 7789.

https://doi.org/10.1182/blood-2024-209567

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Blood (2024) 144 (Supplement 1): 4408.

https://doi.org/10.1182/blood-2024-198056

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 866.

https://doi.org/10.1182/blood-2024-199155

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Poorva Bindal, Marcela Banegas, Rodrigo Paredes, Maria Jose Hernandez Woodbine, Pushan Aggarwal, Jon E. Arnason, Carolyn D Alonso

Blood (2024) 144 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2024-208855

Published: 2024

Journal Articles

Impact of Cardiovascular Diseases on in-Hospital Outcomes of CAR T-Cell Therapy in the United States

Jia Yi Tan, Qi Xuan Ang, Arya Mariam Roy, Nishi Shah, Jon E. Arnason, Yong Hao Yeo

Blood (2024) 144 (Supplement 1): 3724.

https://doi.org/10.1182/blood-2024-206577

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies

John N. Allan, Jennifer L. Crombie, Matthew Matasar, Max S. Topp, Jan Walewski, Tae Min Kim, Won-Seog Kim, Yuan Cheng, Dina Flink, Bertha Fearon Chalet, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Jon E. Arnason

Blood (2024) 144 (Supplement 1): 3118.

https://doi.org/10.1182/blood-2024-199980

Published: 2024

Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic

Blood (2023) 142 (Supplement 1): 427.

https://doi.org/10.1182/blood-2023-179812

Published: 2023

Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell

Blood (2023) 142 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2023-181602

Published: 2023

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2023-178109

Published: 2023

Journal Articles

BCMA-Directed CAR-T Cell Therapy Is Associated with a Higher Risk of Infections: A Systematic Review and Meta-Analysis

Poorva Bindal, Marcela Banegas, Rodrigo Paredes, Maria Jose Hernandez, Pushan Aggarwal, Jon E. Arnason, Carolyn Alonso

Blood (2023) 142 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2023-189225

Published: 2023

Journal Articles

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Poorva Bindal, Pavania Elavalakanar, Caitlin A. Trottier, Laura E. Dodge, Emma K. Logan, David J. Sermer, Michael Leukam, Matthew J Weinstock, Robin M. Joyce, Jessica Liegel, Jacalyn Rosenblatt, David Avigan, Carolyn D. Alonso, Jon E. Arnason

Blood (2022) 140 (Supplement 1): 5238–5240.

https://doi.org/10.1182/blood-2022-167976

Published: 2022

NARROW

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Late Infectious Complications of Chimeric Antigen Receptor T-Cell Therapy Beyond One Year

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Impact of Cardiovascular Diseases on in-Hospital Outcomes of CAR T-Cell Therapy in the United States

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

BCMA-Directed CAR-T Cell Therapy Is Associated with a Higher Risk of Infections: A Systematic Review and Meta-Analysis

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only